Flagship Pioneering-backed Alltrna is once again laying off staff, this time reducing its workforce by 19 people. | Flagship ...

This is a developing story. Please check back for updates. | After a tumultuous tenure marked by recent clashes with the biopharma industry, Vinay Prasad, M.D., will be departing his post as the FDA’s ...

The FDA will end a roughly nine-month hiatus of drug-related advisory committee meetings, with plans to convene its first session of 2026 to scrutinize a pair of oncology applications from AstraZen | ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. | After 27 years with Bavarian Nordic, including 12 as CEO, Paul ...

Having prepared for that outcome, Beam has retained access to the technology under a revised license agreement.

Medtronic and GE HealthCare inked a multiyear deal to expand their more than three-decade- long partnership that aims to boost clinical and technology innovation.

Cognito Therapeutics, which is in late-stage development of its device to treat neurodegenerative diseases like Alzheimer’s, hauled in ...

Zealand Pharma’s Roche-partnered amylin analog demonstrated “placebo-like tolerability” and up to 10.7% mean weight loss at ...

After its latest pipeline clear-out, Merck KGaA is no longer pursuing any clinical-stage cancer candidates obtained through its $3.9 billion ...

In a strikingly blunt briefing, a senior FDA official accused uniQure of pushing “distorted” data to mask a “failed” therapy ...

The back-and-forth between the FDA and gene therapy developer uniQure is getting messier, with an agency spokesperson now denying the biotech’s claims about a sham trial request for the rare ...

Tenaya leverages “human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) with high-throughput in vitro screening, imaging analysis, and machine learning algorithms” to identify new ...